HODGKİN LENFOMA KEMOTERAPİ PROTOKOLLERİ

Kaynaklar:

1-Bonadonna, G., R. Zucali, S. Monfardini, et al. 1975. "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP." Cancer 36(1):252-259.

2- Canellos, G. P., J. R. Anderson, K. J. Propert, et al. 1992. "Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD." N.Engl.J.Med.;327(21):1478-1484.

3- Evens, A. M., J. Cilley, T. Ortiz, et al. 2007. "G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis." Br J Haematol 137(6):545-552.

4- Chisesi, T., M. Federico, A. Levis, et al. 2002. "ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial." Ann Oncol 13 Suppl 1:102-106.

5-Duggan, D. B., G. R. Petroni, J. L. Johnson, et al. 2003. "Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial." J Clin Oncol 21(4):607-614.

6-Federico, M., S. Luminari, E. Iannitto, et al. 2009. "ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial." J Clin Oncol 27(5):805-811.

7-Hoskin, P. J., L. Lowry, A. Horwich, et al. 2009. "Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244." J Clin Oncol 27(32):5390-5396.